Additional file 4: of Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients

Figure S3. NBL tumor of Patient #3 showed area with pathological response to chemotherapy. HE and IHC analysis of the CD68 and CD163 macrophage markers of pre-vaccine, post-chemotherapy FFPE tumor of Patient #3. Images representative for tumor area displaying post-treatment changes with sclerohyalinosis, fibrous reaction with macrophages, and hemosiderin are reported. For HE scale bar = 200 μm, left panel, and 100 μm, right panel; for the IHC of CD68 and CD163, scale bar = 100 μm, left panel, and 50 μm right panel. (PDF 470 kb